Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Rx Plan Candidates Down To The Wire: Applications Due March 23

This article was originally published in The Pink Sheet Daily

Executive Summary

CMS will accept applications from Part D prescription drug plans, Medicare Advantage drug benefit providers and cost contractors. Related reporting requirements are scheduled to be posted on CMS’ website in April.

You may also be interested in...



Part D Plan Sponsors Should Keep It Simple, Blue Cross Exec Says

Sponsors should refrain from offering too many plans in light of the short enrollment period, Independence Blue Cross Senior VP Daniel Lyons suggests at CMS' Advisory Panel on Medicare Education meeting. Independence Blue Cross will offer a basic benefit as well as actuarial equivalent and enhanced alternatives.

Part D Plan Sponsors Should Keep It Simple, Blue Cross Exec Says

Sponsors should refrain from offering too many plans in light of the short enrollment period, Independence Blue Cross Senior VP Daniel Lyons suggests at CMS' Advisory Panel on Medicare Education meeting. Independence Blue Cross will offer a basic benefit as well as actuarial equivalent and enhanced alternatives.

Medicare Part D Plans Can Be Sponsored By Joint Enterprises, CMS Says

The corporate structure will allow plans operating in one state to sponsor a prescription drug benefit in multi-state regions without obtaining licenses in the other states. CMS will require a joint enterprise to enter a single contract, submit a single bid and market the plan under a single name.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel